Director Clinical Development
Revolution Medicines
Director Clinical Development
Revolution Medicines
Clinical-stage oncology company developing RAS inhibitors
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide.
Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency and hold ourselves to a high standard of rigor—all in service of patients.
The Opportunity:
The Director, Clinical Development, Japan will lead the Japan-focused scientific, clinical, and operational scope of assigned study protocols. This role will work with the cross-functional teams for the design, execution, and monitoring of clinical studies, as well as oversee data review, interpretation, and communication to both internal and external stakeholders. Oncology clinical development experience is preferred.
Develop and execute clinical development strategies and the Clinical Development Plan (CDP) with a focus on development in Japan.
Lead cross-functional teams with oversight from senior team members to conduct clinical studies, including study start up, execution and close out activities, data review/analysis, and preparation of study reports.
Oversee the development of program-level documents, including but not limited to clinical protocols, investigator’s brochure, clinical study reports, abstracts and manuscripts, presentations, and various other internal and external documents and communications as needed in Japan.
Oversee ongoing data reviews; prepare and present summaries to internal and external stakeholders.
Ensure trial implementation according to the protocol and analyze information to assess issues relating to protocol conduct and/or individual subject safety.
Represent Clinical Development with Japan-Based internal and external stakeholders (investigators, study sites, vendors, committees, etc.) in support of clinical trial objectives; responds to or triages questions for appropriate escalation.
Conduct literature reviews as needed.
Required Skills, Experience and Education:
BS/MS Degree in a scientific discipline with a minimum 8+ years of experience in the pharmaceutical or biotechnology industry as a clinical scientist or related role.
Proven leadership in a collaborative team setting and driven by a desire to deploy innovative approaches and technologies in a high-energy environment.
Detail-oriented with ability prioritize tasks and function independently as appropriate.
Strong organizational skills and an ability to interpret, discuss, and report trial/program level data effectively and identify trends.
Proficient with software tools (Microsoft Office), Electronic Data Capture, and other custom web-based software.
Excellent written and verbal communication skills both in English and Japanese.
Preferred Skills:
Experience in oncology clinical trials.
Strong experience with clinical data review and data quality assurance.
Knowledge and experience with clinical trial management and oversight.
Understanding and experience in clinical trial protocol and regulatory document authoring.
Revolution Medicines takes protection and security of personal data very seriously and respects your right to privacy while using our website and when contacting us by email or phone. We will only collect, process and use any personal data that you provide to us in accordance with our CCPA Notice and Privacy Policy. For additional information, please contact [email protected].
#LI-RY1 #LI-Hybrid
We are aware of recent recruitment scams in which individuals or organizations falsely represent themselves as being affiliated with Revolution Medicines. These scams may appear as false job advertisements or unsolicited contacts through communication or chat platforms, email, phone, or text message.
Please note that Revolution Medicines does not extend unsolicited employment offers and will never ask candidates to provide financial information, purchase equipment, or pay fees as part of the hiring process. All legitimate communication from Revolution Medicines will come from an official @revmed.com email address.
If you believe you’ve been contacted by someone impersonating a Revolution Medicines recruiter, please report it to [email protected] so we can share these impersonations with our IT team for tracking and awareness.
Clinical-stage oncology company developing RAS inhibitors
Revolution Medicines develops precision oncology drugs focused on cancers driven by RAS mutations. Its RAS(ON) inhibitors are small molecules that bind the active form of RAS to block cancer signaling, with candidates like Daraxonrasib (RMC-6236), Elironrasib (RMC-6291), and Zoldonrasib (RMC-9805) advancing in global Phase 3 trials. The company funds its research through collaborations, royalties, and upfront funding, and has not yet marketed a product. Its goal is to bring effective RAS-targeted therapies to patients and advance multiple candidates through late-stage trials toward approval, supported by strong cash reserves.
Explore more opportunities at Revolution Medicines